Nektar Therapeutics

NKTR Healthcare Biotechnology

Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.

35.78 1.94 −5.14%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
3/9
Altman Z
−17.07
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 4 4
ROE
(180.24%) (217.94%) (53.60%) (35.75%)
ROA
(39.63%) (56.17%) (31.01%) (24.12%)
ROIC
0.00% 0.00% (1,105.34%) (40.20%)
Return on Tangible Assets
(55.42%) (76.39%) (29.75%) (23.51%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(10.05) (12.37) (8.24) (7.08)
Free Cash Flow
(190.35) (208.68) (203.94) (234.03)
Other line items

Show all line items

Columns are period end dates